Mates Sharon has filed 4 insider transactions across 2 companies since November 2025.
Most recent transaction: a grant/award of 49033 shares of Seaport Therapeutics, Inc. ($SPTX) on April 30, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 30, 2026 | Seaport Therapeutics, Inc. | $SPTX | Mates Sharon | Not found | A | Stock Option (Right to Buy) | 49033 | $0.00 | 49,033.0000 | 0 | 9999.99% | 0.00% |
| Jan. 22, 2026 | Benitec Biopharma Inc. | $BNTC | Mates Sharon | Director | A | Options (right to buy) | 31500 | $0.00 | 31,500.0000 | 45,970,516 | 9999.99% | 0.07% |
| Dec. 1, 2025 | Benitec Biopharma Inc. | $BNTC | Mates Sharon | Director | A | Options (right to buy) | 3500 | $0.00 | 3,500.0000 | 37,254,839 | 9999.99% | 0.01% |
| Nov. 5, 2025 | Benitec Biopharma Inc. | $BNTC | Mates Sharon | Director | A | Options (right to buy) | 28517 | $0.00 | 28,517.0000 | 37,254,839 | 9999.99% | 0.08% |